The University of Szeged (SE Hungary) and pharmaceutical company Eli Lilly has signed a cooperation agreement extending to instruction and R+D.
s deputy rector Zoltán Kónya said, the five-year agreement establishes a framework for close cooperation between the university and the pharmaceutical company. They will launch joint programs to raise awareness of diseases and promote prevention, with a particular focus on therapeutic areas such as cardiometabolic diseases, oncology, neurology, and immunology.
Hera Cuku, managing director of Lilly Hungária Ltd., stated that since the University of Szeged has 12 faculties – ranging from medicine and pharmacy through the life sciences to computer science – there is an opportunity for the collaboration to extend beyond the traditional framework of the medical faculty.
At the same time, the expert emphasized that cardiometabolic diseases affect millions of people in Hungary, and Szeged is home to numerous leading experts in the treatment of these diseases. Under the agreement, the university and the pharmaceutical company will jointly organize educational programs and conferences for healthcare professionals, students, and the general public. Lilly Hungária Kft. supports the ongoing professional development of physicians and other healthcare professionals, and the two parties are exploring joint research opportunities to expand their existing scientific collaborations.












